Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Drugs & Aging

• Publication date

  2017-03-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40266-017-0453-yPMID 28349415
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients

  2019cited by this paper
• A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma

  2018cited by this paper
• Hypermutation In Pancreatic Cancer.

  2017cited by this paper
• Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.

  2016cited by this paper
• WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner

  2016cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

  2016cited by this paper
• Autophagy provides metabolic substrates to maintain energy charge and nucleotide pools in Ras-driven lung cancer cells

  2016cited by this paper
• Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy

  2016cited by this paper
• Improving cancer immunotherapy with DNA methyltransferase inhibitors

  2016cited by this paper
• Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities.

  2016cited by this paper
• γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation.

  2016cited by this paper
• Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

  2016cited by this paper
• Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

  2016cited by this paper
• Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors

  2016influential reference
• Ipilimumab and gemcitabine for advanced pancreas cancer: A phase Ib study .

  2016cited by this paper
• Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer

  2016cited by this paper
• The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models

  2016cited by this paper
• Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular-fibrosis and tumor progression

  2016cited by this paper
• Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?

  2016cited by this paper
• DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway

  2016cited by this paper
• Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment

  2016cited by this paper
• Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis.

  2016cited by this paper
• Ibrutinib + durvalumab (MEDI4736) in patients (pts) with relapsed or refractory (R/R) pancreatic adenocarcinoma (PAC): A phase Ib/II multicenter study.

  2016cited by this paper
• A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC).

  2016cited by this paper
• Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

  2016cited by this paper
• MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies

  2016cited by this paper
• LKB1 loss links serine metabolism to DNA methylation and tumorigenesis

  2016cited by this paper
• Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.

  2016cited by this paper
• Abstract PR01: Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell and patient-derived tumor organoids

  2016cited by this paper
• A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

  2016cited by this paper
• Cancer Immunology: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

  2016cited by this paper
• Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?

  2016cited by this paper
• Treating cancer with selective CDK4/6 inhibitors

  2016cited by this paper
• CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

  2016cited by this paper
• Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson.

  2016cited by this paper
• Cancer stem cell signaling pathways

  2016cited by this paper
• The ever-changing landscape of pancreatic cancer stem cells.

  2016cited by this paper
• Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease

  2016cited by this paper
• Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

  2016cited by this paper
• PI3Kγ is a molecular switch that controls immune suppression

  2016cited by this paper
• ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion

  2016cited by this paper
• Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)

  2016cited by this paper
• Genomic analyses identify molecular subtypes of pancreatic cancer

  2016influential reference
• A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer

  2016cited by this paper
• gd T Cells Support Pancreatic Oncogenesis by Restraining ab T Cell Activation Graphical

  2016cited by this paper
• Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.

  2016cited by this paper
• Autophagy and Metabolism

  2016cited by this paper
• PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.

  2016cited by this paper
• RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.

  2016cited by this paper
• A combinatorial strategy for treating KRAS mutant lung cancer

  2016cited by this paper
• Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation.

  2016cited by this paper
• Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells.

  2016cited by this paper
• CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma

  2016cited by this paper
• The Significance of Ras Activity in Pancreatic Cancer Initiation

  2016cited by this paper
• Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma

  2015influential reference
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

  2015cited by this paper
• Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation

  2015influential reference
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer

  2015cited by this paper
• Whole genomes redefine the mutational landscape of pancreatic cancer

  2015influential reference
• Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies

  2015cited by this paper
• Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair12

  2015cited by this paper
• A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

  2015cited by this paper
• ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

  2015cited by this paper
• Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation

  2015cited by this paper
• MEK and PI3K inhibition in solid tumors: rationale and evidence to date

  2015cited by this paper
• Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update

  2015cited by this paper
• Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction

  2015cited by this paper
• P-175Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma

  2015cited by this paper
• The emerging role of Slit-Robo pathway in gastric and other gastro intestinal cancers

  2015cited by this paper
• Perspectives in the treatment of pancreatic adenocarcinoma.

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

  2015cited by this paper
• A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.

  2015cited by this paper
• CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

  2015influential reference
• Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival.

  2015cited by this paper
• SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2

  2015cited by this paper
• Targeting the TGFβ pathway for cancer therapy.

  2015cited by this paper
• Subtyping Pancreatic Cancer.

  2015cited by this paper
• Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

  2015cited by this paper
• The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

  2015cited by this paper
• Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Slit/Robo pathway: a promising therapeutic target for cancer.

  2015cited by this paper
• Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.

  2015cited by this paper
• Cancer: The Ras renaissance

  2015cited by this paper
• Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

  2015cited by this paper
• Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

  2015cited by this paper
• Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

  2015cited by this paper
• A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

  2015cited by this paper
• Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer

  2015cited by this paper
• Curcumin-Mediated HDAC Inhibition Suppresses the DNA Damage Response and Contributes to Increased DNA Damage Sensitivity

  2015cited by this paper
• Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial

  2015cited by this paper

• 19Fluorine‐MRI Based Longitudinal Immuno‐Microenvironment‐Monitoring for Pancreatic Cancer

  2024cites this paper
• Precision Medicine in Pancreatitis: The Future of Acute Pancreatitis Care

  2023cites this paper
• MASTL regulates EGFR signaling to impact pancreatic cancer progression

  2021cites this paper
• Precision Therapy of Pancreatic Cancer: From Bench to Bedside

  2020cites this paper
• Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC.

  2020cites this paper
• Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells

  2019cites this paper
• Predicting tumour growth and its impact on survival in gemcitabine‐treated patients with advanced pancreatic cancer

  2018cites this paper
• New revolution in immunology : PDAC model

  2018cites this paper
• Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

  2018cites this paper
• In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma.

  2018cites this paper
• Berries and other natural products in pancreatic cancer chemoprevention in human clinical trials

  2017cites this paper